Two drugs delivered in combination are better than one after the other for the first-line treatment of men with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations.
That's the conclusion of investigators in the phase 2 BRCAAway trial, which compared a combination of abiraterone (Zytiga) and prednisone plus olaparib (Lynparza) against sequential therapy with the same agents.
At the time of data cutoff, median progression-free survival (PFS), the primary endpoint, was 39 months for patients randomized to the combination compared with 8.4 months for those assigned to abiraterone/prednisone and 14 months for those assigned to olaparib monotherapy, reported Maha Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center in Chicago.
"In patients with metastatic castration-resistant prostate cancer [mCRPC] and BRCA1/2 or ATM alterations, abiraterone and prednisone plus olaparib was well-tolerated and resulted in better progression-free survival and response rates vs single-agent olaparib or abiraterone/prednisone," she said in an oral abstract presentation at the ASCO Genitourinary Cancers Symposium.
Although the study allowed crossover between the single-agent arms at the time of progression, only a few patients made the switch. Nonetheless, in these patients the PFS with the frontline combination was superior to that of sequential therapy, she noted.
Study Rationale and Design
Germline or somatic mutations in genes encoding for homologous recombination-repair occur in about 20% of men with mCRPC. Olaparib, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, interacts with androgen signaling, and preclinical studies have shown that castration-resistant prostate tumor cells have increased PARP1 activity. In addition, PARP1 has been shown preclinically to synergize with androgen receptor pathway inhibitors (ARPIs) such as a biraterone, Dr Hussain explained.
The BRCAAway trial was designed to test whether co-targeting the androgen receptor and PARP1 could result in higher and more durable responses than current frontline therapies in patients with mCRPC with DNA-damage response mutations.
Patients with mCRPC with no prior exposure to either a PARP1 inhibitor, androgen receptor inhibitor, or mCRPC-directed chemotherapy underwent next-generation sequencing and germline testing of tumor tissues, and those patients found to have inactivating BRCA1/2 and/or ATM alterations were randomized on a 1:1:1 basis to either abiraterone 1000 mg daily plus prednisone 5 mg twice daily (19 patients), olaparib 300 mg twice daily (21 patients), or to the combination (21 patients).
The primary endpoint was radiographic PFS according to RECIST 1.1 criteria, Prostate Cancer Working Group 3 criteria, clinical assessment, or death.
As noted, the median PFS was 8.4 months with abiraterone/prednisone, 14 months with olaparib, and 39 months with the combination.
Secondary endpoints also favored the combination therapy arm, with objective response rates of 22%, 14%, and 33%; PSA response rates of 61%, 67%, and 95%; and undetectable PSA response rates of 17%, 14%, and 33%, respectively.
A total of 8 of 19 patients on abiraterone were crossed over to olaparib, and 8 of 21 initially assigned to olaparib were crossed over to abiraterone. In these patients the median PFS from crossover was 8.3 and 7.2 months, respectively. In each crossover group the median PFS from the time of randomization was 16 months.
There were no grade 4 adverse events or treatment-related deaths reported in any of the study arms, and "essentially when you look at the adverse events, they pretty much are consistent with what you would expect to see with these particular agents," Dr Hussain said.
"Overall the patients were tolerating the treatment well," she added.
Practice Changing with Caveats
Kim N. Chi, MD, FRCPC, of the University of British Columbia in Vancouver, Canada, the invited discussant, said that the strengths of the study included an olaparib monotherapy arm — something that was missing from phase 3 trials — that provides insights into how PARP inhibitors perform in this population. He also applauded the inclusion of clinical assessment as a primary endpoint, noting that "this is what we do in routine practice, and therefore, the generalizability of the trial becomes more evident."
The crossover design provides important information about whether an upfront combination or a sequential therapy approach is more effective as well, he added.
He pointed out, however, that the trial was limited by small sample size and by its "horse race" design rather than as a comparison trial.
"So how does the BRCAAway trial change our practice? Despite the limitations, I think it does support an upfront PARP inhibitor-ARPI combination as first-line therapy for HRR gene-mutated metastatic CRPC. These data suggest synergy, and most importantly, there is no loss of opportunity [for more effective therapies]. However, the limitations of the trial will not end this debate today," he said.
The trial was funded by AstraZeneca. Both Dr Hussain and Dr Chi disclosed honoraria, consulting/advising, and institutional research funding from AstraZeneca and others.
This article originally appeared on MDedge.com, part of the Medscape Professional Network.Â
Â